A review of novel therapies for melanoma

American Journal of Clinical Dermatology

Volumn 15, Issue 4, 2014, Pages 323-337

  Karimkhani, Chante ^a   Gonzalez, Rene ^b   Dellavalle, Robert P ^c,d,e  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d Food Science and Human Nutrition   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; B RAF KINASE INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; TALIMOGENE LAHERPAREPVEC; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ANTINEOPLASTIC AGENT;

ANTIANGIOGENIC ACTIVITY; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL DIVISION; CELLULAR SECRETION; CYTOLYSIS; DRUG SENSITIVITY; DRUG TOXICITY; GENE MUTATION; HUMAN; LIGAND BINDING; MELANOMA; METASTATIC MELANOMA; ONCOGENE C KIT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TUMOR IMMUNITY; TUMOR INVASION; TUMOR REGRESSION; UVEA MELANOMA; DRUG DESIGN; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; SKIN NEOPLASMS;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; IMMUNOTHERAPY; MELANOMA; MOLECULAR TARGETED THERAPY; SKIN NEOPLASMS;

EID: 84904467824     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-014-0083-7     Document Type: Review

References (89)

1. Rigel DS, Russak J, Friedman R. The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J Clin. 2010;60(5):301-16.
2. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC Cancer-Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc. fr. Accessed 3 Feb 2014.
3. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199.
4. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635-48. (Pubitemid 32786276)
5. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29(10):1239-46.
6. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135-47. (Pubitemid 41653105)
7. Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol. 2011;8(7):426-33.
8. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855-67. (Pubitemid 38410730)
9. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16.
10. US Food and Drug Administration. FDA news release: FDA approves Zelboraf and companion diagnostic test for late-stage skin cancer. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm268241.htm. Accessed 9 Feb 2014.
11. Onco'Zine. First personalized cancer medicine allows patients with deadly form of metastatic melanoma to live significantly longer. http://oncozine.com/ profiles/blogs/first-personalized-cancer-medicine-allows-patients-deadly-form- of. Accessed 9 Feb 2014.
12. Chapman PB, Hauschild A, Robert C, et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (VEM) with dacarbazine (DTIC) in previously untreated patients with BRAF V600E-mutated melanoma. J Clin Oncol, ASCO Annual Meeting Abstract 2012;30(suppl):8502.
13. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF. N Engl J Med. 2012;366(3):207-15.
14. Hauschild A, Grob J, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-65.
15. Hauschild A, Grob JJ, Demidov LV, et al. Phase III, randomized, open-label, multicenter trial (BREAK-3) comparing the BRAF kinase inhibitor dabrafenib (GSK2118436) with dacarbazine (DTIC) in patients with BRAF V600E-mutated melanoma. J Clin Oncol, ASCO Annual Meeting Abstract 2012;30(suppl):LBA8500.
16. Lee CI, Menzies AM, Haydu L, et al. Correlates of fever in patients (pts) receiving combined dabrafenib (GSK2118436) plus trametinib (GSK1120212) for V600 BRAF-mutant metastatic melanoma (MM). J Clin Oncol, ASCO Annual Meeting Abstracts 2012;30(suppl):E19011.
17. Kefford R, Miller WH, Shao-Weng D, et al. Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK 1/2 inhibitor MEK162 in BRAFV600-dependent advanced solid tumors. J Clin Oncol, ASCO Annual Meeting Abstract 2013;31(suppl):9029.
18. Nakamura A, Arita T, Tsuchiya S, et al. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Cancer Res. 2013;73(23):7043-55.
19. Gonzalez D, Fearfield L, Nathan P, et al. BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel. Br J Dermatol. 2013;168(4):700-7.
20. Halait H, Demartin K, Shah S, et al. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diagn Mol Pathol. 2012;21(1):1-8.
21. Cobas® 4800 BRAF V600 Mutation Test Package Insert. Roche Molecular Systems, Inc. August 2011.
22. US Food and Drug Administration. THxID™-BRAF kit for use on the ABI 7500 Fast Dx Real-Time PCR Instrument-P120014. BioMérieux labeling, May 2013. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma.cfm?num= p120014. Accessed 2 Mar 2014.
23. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707-14.
24. Chapman PB. Mechanisms of resistance to RAF inhibition in melanomas harboring a BRAF mutation. Am Soc Clin Oncol Educ Book 2013: 80-2.
25. Qi M, Elion EA. MAP kinase pathways. J Cell Sci. 2005;118(Pt 16):3569-72. (Pubitemid 41309404)
26. US Food and Drug Administration. Trametinib. http://www.fda.gov/Drugs/ InformationOnDrugs/ApprovedDrugs/ucm354478.htm. Accessed 12 Feb 2014.
27. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107-14.
28. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012;366:207-15.
29. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694-703.
30. US Food and Drug Administration. Trametinib and dabrafenib. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm381451.htm. Accessed 17 Feb 2014.
31. GlaxoSmithKline. A study comparing trametinib and dabrafenib combination therapy to dabrafenib monotherapy in subjects with BRAF-mutant melanoma [ClinicalTrials.gov identifier NCT01584648]. US National Institutes of Health, ClinicalTrials. gov [online]. http://clinicaltrials.gov/show/NCT01584648. Accessed 20 Aug 2013.
32. GlaxoSmithKline. Dabrafenib plus trametinib vs vemurafenib alone in unresectable or metastatic BRAF V600E/K cutaneous melanoma (COMBI-v) [ClinicalTrials.gov identifier NCT015 97908]. http://clinicaltrials.gov/show/ NCT01597908. Accessed 20 Aug 2013.
33. Hoffman La Roche. A phase 3 study comparing GDC-0973, a MEK inhibitor, in combination with vemurafenib vs vemurafenib alone in patients with metastatic melanoma [ClinicalTrials.gov identifier NCT01689519]. http://clinicaltrials.gov/ show/NCT01689519. Accessed 25 Aug 2013.
34. Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110(5):956-61. (Pubitemid 36560496)
35. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010;363(23):2191-9.
36. Carvajal RD, Sosman JA, Quevedo F, et al. Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma. J Clin Oncol, ASCO Annual Meeting Abstract 2013;31(suppl):9003.
37. Alexeev V, Yoon K. Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol. 2006;126(5):1102-10.
38. Ko JM, Velez NF, Tsao H. Pathways to melanoma. Semin Cutan Med Surg. 2010;29(4):210-7.
39. Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist. 2004;9(3):271-81. (Pubitemid 38756876)
40. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327-34.
41. Carvajal RD, Antonescu CR, Wolchok JD, et al. Supplementary appendix to: KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327-34.
42. Todd JR, Becker TM, Kefford RF, et al. Secondary c-kit mutations confer acquired resistance to RTK inhibitors in c-kit mutant melanoma cells. Pigment Cell Melanoma Res. 2013;26(4):518-26.
43. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant BCRABL. Cancer Cell. 2005;7(2):129-41. (Pubitemid 40248339)
44. US Food and Drug Administration. Nilotinib (Tasigna). http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/ CDER/ucm216218.htm. Accessed 12 Feb 2014.
45. Cho JH, Kim KM, Kwon M, et al. Nilotinib in patients with metastatic melanoma harboring kit gene aberration. Invest New Drugs. 2012;30(5):2008-14.
46. Dana-Farber Cancer Institute; Brigham and Women's Hospital; Beth Israel Deaconess Medical Center; Massachusetts General Hospital; Novartis. Nilotinib in TKI resistant or intolerant patients with metastatic mucosal, acral, or chronically sun damaged melanoma [ClinicalTrials.gov identifier NCT00788775]. http://clinicaltrials.gov/show/NCT00788775. Accessed 25 Aug 2013.
47. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47(27):6658-61. (Pubitemid 40053752)
48. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399-401. (Pubitemid 38938156)
49. Kluger HM, Dudek AZ, McCann C, et al. A phase 2 trial of dasatinib in advanced melanomas. Cancer. 2011;117(10):2202-8.
50. Eastern Cooperative Oncology Group; National Cancer Institute. Dasatinib in treating patients with locally advanced or metastatic mucosal melanoma, acral melanoma, or vulvovaginal melanoma that cannot be removed by surgery [ClinicalTrials.gov identifier NCT00700882]. http://clinicaltrials.gov/show/ NCT00700882. Accessed 28 Aug 2014.
51. Corrie PG, Basu B, Zaki KA. Targeting angiogenesis in melanoma: prospects for the future. Ther Adv Med Oncol. 2010;2(6):367-80.
52. Graells J, Vinyals A, Figueras A, et al. Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol. 2004;123(6):1151-61. (Pubitemid 39586840)
53. Goydos JS, Gorski DH. Vascular endothelial growth factor CmRNA expression correlates with stage of progression in patients with melanoma. Clin Cancer Res. 2003;9(16 Pt 1):5962-7. (Pubitemid 38018082)
54. National Cancer Institute. FDA approval for bevacizumab. http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab. Accessed 31 Jul 2013.
55. Kim KB, Sosman JA, Fruehauf JP, et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol. 2012;30(1):34-41.
56. Haukeland University Hospital, The Norwegian Melanoma Group and the Norwegian Cancer Association. Bevacizumab versus dacarbazine in metastatic melanoma [ClinicalTrials.gov identifier NCT01705392]. http://clinicaltrials.gov/ show/NCT01705392. Accessed 28 Aug 2013.
57. Corrie P, Marshall A, Goonewardena M, et al. Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: preplanned interim results for the AVAST-M trial. J Clin Oncol, ASCO Annual Meeting Abstract 2013;31(suppl):9000.
58. ImClone LLC. A study of ramucirumab with or without dacarbazine in metastatic malignant melanoma [ClinicalTrials.gov identifier NCT00533702]. http://clinicaltrials.gov/show/NCT00533702. Accessed 25 Aug 2013.
59. Tarhini AA, Frankel P, Margolin KA, et al. Aflibercept (VEGF Trap) in inoperable stage III or stage IV melanoma of cutaneous or uveal origin. Clin Cancer Res. 2011;17(20):6574-81.
60. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-64.
61. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol. 2009;27:591-619.
62. Lee B, Mukhi N, Liu D. Current management and novel agents for malignant melanoma. J Hematol Oncol. 2012;5(3):1-7.
63. US Food and Drug Administration. FDA approves new treatment for a type of late-stage skin cancer. http://www.fda.gov/news events/newsroom/ pressannouncements/ucm1193237.htm. Accessed 12 Feb 2014.
64. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-26.
65. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.
66. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10(9):909-15. (Pubitemid 39273730)
67. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-20.
68. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691-7.
69. Chin K, Ibrahim R, Berman D, et al. Treatment guidelines for the management of immune-related adverse events in patients treated with ipilimumab, and anti-CTLA4 therapy. Ann Oncol. 2008;19(8 Suppl):viii244-5.
70. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24(2):207-12.
71. Ribas A. Tumor immunotherapy directed at PD-1. NEJM. 2012;366(26):2517-9.
72. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54.
73. Sznol M, Kluger HM, Hodi FS, et al. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol, ASCO Annual Meeting Abstract 2013;31(suppl):CRA9006.
74. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134-44.
75. Merck. Study of MK-3475 (lambrolizumab) in participants with progressive locally advanced or metastatic carcinoma, melanoma, or non-small cell lung carcinoma (P07990/MK-3475-001 AM7) [ClinicalTrials.gov identifier NCT01295827]. http://clinicaltrials.gov/show/NCT01295827. Accessed 20 Aug 2013.
76. Hamid O, Sosman JA, Lawrence DP, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma. J Clin Oncol, ASCO Annual Meeting Abstract 2013;31(suppl):CRA9010.
77. Wolchock JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-33.
78. Bristol-Myers Squibb. Phase 3 study of nivolumab or nivolumab plus ipilimumab versus ipilimumab alone in previously untreated advanced melanoma [ClinicalTrials.gov identifier NCT0184 4505]. http://clinicaltrials.gov/show/ NCT01844505. Accessed 20 Aug 2013.
79. Liu C, Peng W, Xu C, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013;19(2):393-403.
80. Ribas A, Hodi FS, Callahan M, et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013;368(14):1365-6.
81. Shi Y, Liu CH, Roberts AI, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res. 2006;16(2):126-33. (Pubitemid 43247967)
82. Hodi FS, Lee SJ, McDermott DF, et al. Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608. J Clin Oncol, ASCO Annual Meeting Abstract 2013;31(suppl):9007.
83. The ASCO Post. ASCO 2013: adding GM-CSF to ipilimumab significantly improves survival for patients with metastatic melanoma. http://www.ascopost. com/ViewNews.aspx?nid=4188. Accessed 1 Feb 2014.
84. Liu BL, Robinson M, Han Z-Q, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003;10(4):292-303. (Pubitemid 36305598)
85. Kaufman HL, Kim DW, DeRaffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIC and IV melanoma. Ann Surg Oncol. 2010;17(3):718-30.
86. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patents with unresectable metastatic melanoma. J Clin Oncol. 2009;27(334):5763-71.
87. Andtbacka RHI, Collichio FA, Amatruda T, et al. OPTiM: a randomized phase iii trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol, ASCO Annual Meeting Abstract 2013;31(suppl):9008.
88. Hersh E, Del Vecchio M, Brown M, et al. Phase 3, randomized, open-label, multicenter trial of nab-paclitaxel (nab-P) versus dacarbazine (DTIC) in previously untreated patients with metastatic malignant melanoma [abstract]. Pigment Cell Melanoma Res. 2012;25(6):863-903.
89. Hersh E, Del Vecchio M, Brown MP, et al. A phase III trial of nabpaclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma: a subanalysis based on BRAF status. J Clin Oncol, ASCO Annual Meeting Abstract 2013;31(suppl):9030.